WILMINGTON, DE — NiKang Therapeutics® Inc. has achieved a pivotal step in the development of its first-in-class CDK2 degrader, NKT3964, by completing the dosing of the first patient cohort in a ...
"We are excited to outline a clear path for Zentalis to bring azenosertib to patients with Cyclin E1+ PROC,” said Ingmar Bruns, M.D., Chief Medical Officer. "In a patient population with a clear unmet ...
γ-herpesvirus genomes encode an abundance of homologues of cellular factors, including cyclin and Bcl-2. These viral homologues differ from their cellular counterparts in that the viral proteins ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback